Hepion Pharmaceuticals Receives European Patent for Rencofilstat
Patent Covers 38 European Countries
Rencofilstat’s Exclusivity May Extend into 2048
EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announced today that the European Patent Office (EPO) has decided to grant a European patent for its lead drug candidate, Rencofilstat.
The patent covers 38 European countries, providing protection for Rencofilstat’s innovative AI-driven therapeutic approach in the treatment of various liver diseases. The exclusivity granted by this patent may extend into 2048, giving Hepion Pharmaceuticals a significant competitive advantage in the European market.
Rencofilstat is a novel drug candidate that has shown promising results in preclinical and clinical studies for the treatment of NASH, fibrosis, and HCC. By harnessing the power of AI in drug development, Hepion Pharmaceuticals aims to revolutionize the treatment of liver diseases and improve patient outcomes.
The EPO’s decision to grant a European patent for Rencofilstat highlights the innovative nature of Hepion Pharmaceuticals’ approach to drug development and underscores the potential of AI technology in the pharmaceutical industry. This milestone represents a significant step forward for the company and reaffirms its commitment to bringing cutting-edge treatments to patients in need.
How Will This Affect Me?
As a patient with liver disease, the granting of a European patent for Rencofilstat by the EPO could mean access to a groundbreaking treatment option that leverages AI technology for personalized care. This could lead to improved outcomes, better quality of life, and potentially a longer lifespan for individuals suffering from NASH, fibrosis, HCC, and other chronic liver diseases.
How Will This Affect the World?
The EPO’s decision to grant a European patent for Rencofilstat signifies a major advancement in the field of AI-driven drug development and its potential to revolutionize the treatment of liver diseases on a global scale. This innovative approach has the potential to transform the standard of care, improve patient outcomes, and pave the way for future advancements in pharmaceutical research and development.
Conclusion
The European Patent Office’s decision to grant a European patent for Rencofilstat is a significant milestone for Hepion Pharmaceuticals and a testament to the company’s commitment to innovation in drug development. This achievement not only solidifies Hepion Pharmaceuticals’ position in the European market but also has the potential to impact patients worldwide by offering a novel treatment option for liver diseases. With Rencofilstat’s exclusivity potentially extending into 2048, the future looks promising for Hepion Pharmaceuticals and the millions of individuals affected by liver diseases globally.
